Genomics Bioscience & Technology Co Net Debt / EBITDA
The Net Debt to EBITDA of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 18, 2026 is -4.04. In the previous year, Net Debt to EBITDA was -2.36 — a change of 71.42% (lower).
Get this data via API
Financial Data API
Net Debt / EBITDA
-4.04
YoY
71.42%
Last updated:
The Genomics Bioscience & Technology Co Net Debt / EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Net Debt / EBITDA | YoY |
|---|---|---|
| -4.04 | +71.42% | |
| -2.36 | +2,003.50% | |
| -0.11 | -91.45% | |
| -1.31 | -45.74% | |
| -2.42 | -98.86% | |
| -211.19 | +637.86% | |
| -28.62 | -435.45% | |
| 8.53 | +24.39% | |
| 6.86 | +33.65% | |
| 5.13 | -37.59% | |
| 8.22 | +67.93% | |
| 4.90 | +589.96% | |
| 0.71 | -37.92% | |
| 1.14 | -93.56% | |
| 17.74 | -623.75% | |
| -3.39 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genomics Bioscience & Technology Co Stock analysis
Frequently Asked Questions about Genomics Bioscience & Technology Co stock
Net Debt to EBITDA of Genomics Bioscience & Technology Co is -4.04 in 2025.
Net Debt to EBITDA of Genomics Bioscience & Technology Co changed from -2.36 to -4.04, representing a 71.42% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Net Debt to EBITDA Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.
Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Genomics Bioscience & Technology Co with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — Genomics Bioscience & Technology Co
All Key Metrics — Genomics Bioscience & Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth